Immunocore Holdings (IMCR) said Monday it has dosed the first patient in a phase 1 trial of IMC-P115C, a half-life extended Immune mobilizing monoclonal T-cell receptor against cancer, or ImmTAC, candidate.
The drug candidate was developed to improve patient convenience by reducing the frequency of treatment administration, the company said.
The phase 1 trial will assess the safety, pharmacokinetics and clinical activity of IMC-P115C in patients with a specific type of advanced solid tumor.
According to the company, ImmTAC molecules are designed to redirect the immune system to recognize and kill cancerous cells.
Shares of the company rose more than 5% in recent premarket activity Monday.
Price: 30.00, Change: +1.67, Percent Change: +5.91
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。